Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb 22:2:16.
doi: 10.3389/fcimb.2012.00016. eCollection 2012.

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials

Fabio Bagnoli  1 , Sylvie Bertholet, Guido Grandi
Affiliations
Review

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials

Fabio Bagnoli et al. Front Cell Infect Microbiol. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
A model to generate protective immunity against S. aureus infections through vaccination. Protective vaccines should be able to elicit three major immune responses: (i) antibodies to directly inhibit bacterial viability and/or toxicity; (ii) antibodies to mediate opsonophagocytosis; and (iii) cell-mediated immunity to stimulate recruitment of phagocytes (e.g., neutrophils) at the site of the infection
See this image and copyright information in PMC

References

    1. Arrecubieta C., Matsunaga I., Asai T., Naka Y., Deng M. C., Lowy F. D. (2008). Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J. Infect. Dis. 198, 571–575 10.1086/590210 - DOI - PMC - PubMed
    1. Baudner B. C., Ronconi V., Casini D., Tortoli M., Kazzaz J., Singh M., Hawkins L. D., Wack A., O'Hagan D. T. (2009). MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26, 1477–1485 10.1007/s11095-009-9859-5 - DOI - PubMed
    1. Bubeck Wardenburg J., Schneewind O. (2008). Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205, 287–294 10.1084/jem.20072208 - DOI - PMC - PubMed
    1. Cheng A. G., Kim H. K., Burts M. L., Krausz T., Schneewind O., Missiakas D. M. (2009). Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 23, 3393–3404 10.1096/fj.09-135467 - DOI - PMC - PubMed
    1. Clarke S. R., Brummell K. J., Horsburgh M. J., Mcdowell P. W., Mohamad S. A., Stapleton M. R., Acevedo J., Read R. C., Day N. P., Peacock S. J., Mond J. J., Kokai-Kun J. F., Foster S. J. (2006). Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 193, 1098–1108 10.1086/501471 - DOI - PubMed

MeSH terms

Substances